• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Autoimmune disease

Read More
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Cardiovascular disease

Read More
BioCentury | Jun 10, 2010
Distillery Therapeutics

Indication: Cancer

Read More
BioCentury | May 8, 2006
Clinical News

Nexavar sorafenib: Completed Phase III enrollment

Read More
BioCentury | Nov 7, 2005
Clinical News

Nexavar sorafenib: Interim Phase III data

Read More
BioCentury | Sep 19, 2005
Company News

Onyx names Fuchs CMO

Read More
BioCentury | Sep 19, 2005
Clinical News

Sorafenib regulatory update

Read More
BioCentury | Sep 19, 2005
Clinical News

Sorafenib: Phase III start

Read More
BioCentury | Sep 15, 2005
Company News

FDA accepts sorafenib NDA

Read More
BioCentury | Sep 13, 2005
Company News

Bayer, Onyx submit sorafenib MAA

Read More
Items per page:
1 - 10 of 94